Comparison of risk stratification models for pregnancy in congenital heart disease.


Journal

International journal of cardiology
ISSN: 1874-1754
Titre abrégé: Int J Cardiol
Pays: Netherlands
ID NLM: 8200291

Informations de publication

Date de publication:
15 01 2021
Historique:
received: 01 07 2020
revised: 07 09 2020
accepted: 10 09 2020
pubmed: 16 9 2020
medline: 28 5 2021
entrez: 15 9 2020
Statut: ppublish

Résumé

Pregnancy in women with congenital heart disease (CHD) is associated with increased risk for maternal cardiac complications. Several risk stratification models are used to predict adverse cardiac outcome in women with CHD who become pregnant. This study was set up as an exploratory study to provide a head-to-head comparison of the 4 most commonly used models: CARPREG, CARPREG II and ZAHARA risk scores and mWHO risk classification. We randomly selected 100 women from the database of paediatric and congenital heart disease of the University Hospitals Leuven. Individual pregnancy risk scores were retrospectively calculated and summarized in a weighted average risk for each risk stratification model. To evaluate accuracy of each model, the weighted average risk was plotted against the actual observed number of "cardiac events" as defined in the respective risk models. Maternal adverse cardiac events occurred in 8% of our study population. Weighted average risks were plotted versus the observed number of events for each model: 10.1% versus 4.0% for CARPREG, 8.6% versus 5.0% for CARPREG II, 11.1% versus 8.0% for ZAHARA and 12.4% versus 8.0% for the mWHO classification. All risk models overestimated maternal cardiac risk. The ZAHARA risk model appeared to be a closer reflection of maternal risk in our cohort of CHD patients. More research on a larger study population is needed.

Sections du résumé

BACKGROUND
Pregnancy in women with congenital heart disease (CHD) is associated with increased risk for maternal cardiac complications. Several risk stratification models are used to predict adverse cardiac outcome in women with CHD who become pregnant. This study was set up as an exploratory study to provide a head-to-head comparison of the 4 most commonly used models: CARPREG, CARPREG II and ZAHARA risk scores and mWHO risk classification.
METHODS AND RESULTS
We randomly selected 100 women from the database of paediatric and congenital heart disease of the University Hospitals Leuven. Individual pregnancy risk scores were retrospectively calculated and summarized in a weighted average risk for each risk stratification model. To evaluate accuracy of each model, the weighted average risk was plotted against the actual observed number of "cardiac events" as defined in the respective risk models. Maternal adverse cardiac events occurred in 8% of our study population. Weighted average risks were plotted versus the observed number of events for each model: 10.1% versus 4.0% for CARPREG, 8.6% versus 5.0% for CARPREG II, 11.1% versus 8.0% for ZAHARA and 12.4% versus 8.0% for the mWHO classification.
CONCLUSION
All risk models overestimated maternal cardiac risk. The ZAHARA risk model appeared to be a closer reflection of maternal risk in our cohort of CHD patients. More research on a larger study population is needed.

Identifiants

pubmed: 32931856
pii: S0167-5273(20)33814-6
doi: 10.1016/j.ijcard.2020.09.033
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

54-60

Informations de copyright

Copyright © 2020 Elsevier B.V. All rights reserved.

Auteurs

Nathalie Denayer (N)

Faculty of Medicine, Department of Internal Medicine, KU Leuven, Belgium.

Els Troost (E)

Division of Structural and Congenital Cardiology, University Hospitals Leuven, Belgium.

Béatrice Santens (B)

Division of Structural and Congenital Cardiology, University Hospitals Leuven, Belgium.

Pieter De Meester (P)

Division of Structural and Congenital Cardiology, University Hospitals Leuven, Belgium; Department of Cardiovascular Sciences, KU Leuven, Belgium.

Leen Roggen (L)

Division of Structural and Congenital Cardiology, University Hospitals Leuven, Belgium.

Philip Moons (P)

Department of Public Health and Primary Care, KU Leuven, Belgium; Institute of Health and Care Science, University of Gothenburg, Sweden; Department of Paediatrics and Child Health, University of Cape Town, South Africa.

Kristel Van Calsteren (K)

Department of Obstetrics and Gynecology, University Hospitals Leuven, Belgium.

Werner Budts (W)

Division of Structural and Congenital Cardiology, University Hospitals Leuven, Belgium; Department of Cardiovascular Sciences, KU Leuven, Belgium.

Alexander Van De Bruaene (A)

Division of Structural and Congenital Cardiology, University Hospitals Leuven, Belgium; Department of Cardiovascular Sciences, KU Leuven, Belgium. Electronic address: alexander.vandebruaene@uzleuven.be.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH